Entering text into the input field will update the search result below

NeuroBo stock rises ~10% on FDA nod to start trial of liver drug

May 02, 2023 8:26 AM ETNeuroBo Pharmaceuticals, Inc. (NRBO)By: Ravikash, SA News Editor
FDA written on wooden cube with keyboard , calculator, chart,glasses.Business concept

Iryna Drozd

  • The U.S. Food and Drug Administration (FDA) cleared NeuroBo Pharmaceuticals' (NASDAQ:NRBO) investigational new drug (IND) application seeking to start a trial of liver disease drug DA-1241.
  • The company plans to begin a two-part, phase 2a trial of DA-1241 to treat nonalcoholic steatohepatitis (NASH) in Q3 2023.
  • The study will include people with presumed NASH and confirmed pre-diabetes or type 2 diabetes mellitus (T2DM).
  • "In Phase 1a/1b clinical studies, DA-1241 was well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM)," said Joe Hooker, interim president and CEO, NeuroBo.
  • NRBO +12.41% to $0.77 premarket May 2

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.